The Experts below are selected from a list of 6144 Experts worldwide ranked by ideXlab platform
David A. Morrow - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.
Journal of the American Heart Association, 2019Co-Authors: Thomas A. Zelniker, Petr Jarolim, Benjamin M. Scirica, Eugene Braunwald, Jeong-gun Park, Saumya Das, Marc S. Sabatine, David A. MorrowAbstract:Background Small studies have suggested an association between markers of collagen turnover and adverse outcomes in heart failure ( HF ). We examined C-Terminal Telopeptide (beta- CT x) and the risk of cardiovascular death or new or worsening HF in non- ST -elevation acute coronary syndrome. Methods and Results We measured baseline serum beta- CT x, NT -pro BNP (N-terminal pro-B-type natriuretic peptide), hsTnT (high-sensitivity cardiac troponin T) and hs CRP (high-sensitivity C-reactive protein) (Roche Diagnostics) in a nested biomarker analysis (n=4094) from a study of patients with non- ST -elevation acute coronary syndrome. The relationship between quartiles of beta- CT x and cardiovascular death or HF over a median follow-up time of 12 months was analyzed using adjusted Cox models. Higher beta- CT x levels identified a significantly higher risk of cardiovascular death/ HF (Q4 10.9% versus Q1 3.8%, Logrank P
-
PROGNOSTIC VALUE OF BIOMARKER OF COLLAGEN TURNOVER (C-Terminal Telopeptide) IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM MERLIN-TIMI 36
Journal of the American College of Cardiology, 2018Co-Authors: Thomas A. Zelniker, Petr Jarolim, Benjamin M. Scirica, Eugene Braunwald, Jeong-gun Park, Saumya Das, Marc S. Sabatine, David A. MorrowAbstract:Small studies have suggested an association between markers of collagen turnover and adverse outcomes in patients with heart failure. We examined the relationship between C-Terminal Telopeptide (CTX) and the risk of hospitalization for heart failure (HHF) and cardiovascular death (CVD) in pts with
B. E. Christopher Nordin - One of the best experts on this subject based on the ideXlab platform.
-
Suppression of C-Terminal Telopeptide in hypovitaminosis D requires calcium as well as vitamin D.
Calcified tissue international, 2010Co-Authors: S. Devika C. Thomas, Allan G. Need, B. E. Christopher NordinAbstract:We compared the effects of oral calcium and vitamin D separately and together on relevant variables in 22 postmenopausal volunteers with initial serum 25OHD levels below 60 nmol/L. Subjects were allocated randomly to two regimens: group 1 received 1 week of calcium 1,000 mg, followed by 7 weeks with additional vitamin D3 1,000 i.u. daily; group 2 received 7 weeks of D3 1,000 i.u. daily, followed by 1 week with additional calcium 1,000 mg. We measured serum calcium, phosphate, PTH, 25OHD, CTX, and ALP at baseline and after 1 and 8 weeks in group 1 and after 7 and 8 weeks in group 2. There were no significant changes in ALP from either vitamin D or calcium. Calcium caused significant elevation of serum 25OHD as well as major suppression of serum CTX, which could not easily be accounted for by suppression of PTH. Vitamin D caused no significant change in any variable except elevation of serum 25OHD. The suppressive effect of calcium (whether given first or second) on serum CTX was threefold greater than that of vitamin D (whether given first or second) (P < 0.001), although their suppressive effects on serum PTH were the same. Calcium and vitamin D yielded greater and more significant effects on all variables (except ALP) than either treatment alone. We suggest that calcium may elevate serum 25OHD by prolonging its half-life and that it may have an inhibitory effect on bone resorption independent of, or in addition to, its suppression of PTH.
-
Suppression of Parathyroid Hormone and Bone Resorption by Calcium Carbonate and Calcium Citrate in Postmenopausal Women
Calcified Tissue International, 2008Co-Authors: Sunethra D. C. Thomas, Allan G. Need, Graeme Tucker, Peter Slobodian, Peter D. O’loughlin, B. E. Christopher NordinAbstract:This study was conducted to compare the suppressive effects of calcium carbonate and calcium citrate on bone resorption in early postmenopause. Calcium citrate is thought to be better absorbed. We therefore tested the hypothesis that calcium as citrate is more effective than calcium as carbonate in suppressing parathyroid hormone (PTH) and C-Terminal Telopeptide. Twenty-five healthy postmenopausal women were recruited in this double blind crossover study. The subjects were randomly allocated to receive either 1,000 mg of elemental calcium as carbonate or 500 mg of calcium as citrate. They were given the alternate calcium dose 1 week later. Serum measurements of total and ionized calcium, phosphate, PTH, and CrossLaps were repeated 12 hours after each dose. Analysis of variance found no significant difference between measures for the two salts. Tests for equivalence indicated that 500 mg of calcium citrate may be superior to 1,000 mg of calcium carbonate in raising serum total and ionized calcium ( P = 0.04 and 0.05, respectively). For all parameters measured, 500 mg of calcium citrate was at least as beneficial as 1,000 mg of calcium carbonate. Calcium citrate is at least as effective as calcium carbonate in suppressing PTH and C-Terminal Telopeptide cross-links, at half the dose. This may be because calcium as citrate is better absorbed than calcium as carbonate. If calcium citrate can be used in lower doses, it may be better tolerated than calcium carbonate.
M. Locatelli - One of the best experts on this subject based on the ideXlab platform.
-
European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-Terminal Telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibrobla
Osteoporosis International, 2020Co-Authors: E. Cavalier, P. Lukas, M. Bottani, A.k. Aarsand, F. Ceriotti, A. Coşkun, J. Díaz-garzón, P. Fernàndez-calle, E. Guerra, M. LocatelliAbstract:We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Introduction Within-subject (CV_I) and between-subject (CV_G) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-Terminal Telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). Methods In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. Results We found no effect of gender upon the CV_I estimates. The following CV_I estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4–16.0%), PINP 8.8% (8.4–9.3%), OC 8.9% (8.5–9.4%), iFGF23 13.9% (13.2–14.7%), and uCuP-MGP 6.9% (6.1–7.3%). Conclusions The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.
-
European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-Terminal Telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibrobla
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteopor, 2020Co-Authors: E. Cavalier, P. Lukas, M. Bottani, A.k. Aarsand, F. Ceriotti, A. Coşkun, J. Díaz-garzón, P. Fernàndez-calle, E. Guerra, M. LocatelliAbstract:We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Within-subject (CVI) and between-subject (CVG) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-Terminal Telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. We found no effect of gender upon the CVI estimates. The following CVI estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4–16.0%), PINP 8.8% (8.4–9.3%), OC 8.9% (8.5–9.4%), iFGF23 13.9% (13.2–14.7%), and uCuP-MGP 6.9% (6.1–7.3%). The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.
Harry Sprot - One of the best experts on this subject based on the ideXlab platform.
-
Associations of CTX-II with biochemical markers of bone turnover raise questions about its tissue origin: data from CHECK, a cohort study of early osteoarthritis
Annals of the rheumatic diseases, 2013Co-Authors: Harry SprotAbstract:I read with interest this paper by van Spil et al 1 examining further the osteoarthritis biomarker CTX-II (C-Terminal Telopeptide of type II collagen) and note the suspicions of the authors that this marker might be linked to bone metabolism. High correlation with biomarkers of bone and CTX-II were noted and also a characteristic increase around the time of the menopause. However, it has been …
M. Takahashi - One of the best experts on this subject based on the ideXlab platform.
-
Sequential Changes of Bone Metabolism in Normal and Delayed Union of the Spine
Clinical Orthopaedics and Related Research, 2008Co-Authors: Tsuyoshi Ohishi, M. Takahashi, Akihiro Yamanashi, Daisuke Suzuki, Akira NaganoAbstract:Time-dependent changes in bone markers in delayed or nonunion of vertebral fracture were compared with those of normal union. Thirty-three patients with a fresh vertebral fracture were enrolled. Urinary Type I collagen C-Terminal Telopeptide, pyridinoline, deoxypyridinoline, serum C-Terminal Telopeptide, and N-midportion of osteocalcin (OC_N-mid) were determined at the time of hospital admission (within 24 hours after the fracture event in all cases) and at 2, 4, 12, 24, and 48 weeks thereafter. Subjects were divided into two groups according to the results of MR images taken 48 weeks after fracture. Twenty-four were normally united (Group N) and nine had delayed or nonunion (Group D) of the spine. No differences between values of bone resorption markers in Group N and Group D were observed at any time. Serum OC_N-mid in Group N started to increase at 2 weeks and reached the peak value at 24 weeks (180%); however, serum OC_N-mid in Group D increased at most 120% from baseline to 4 weeks. Values of serum OC_N-mid in Group N were higher at 24 and 48 weeks than those in Group D. Impairment of fracture healing was strongly associated with a deficit in the increase of osteocalcin in the later stage of fracture repair. Level of Evidence: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
-
Sequential Changes of Bone Metabolism in Normal and Delayed Union of the Spine
Clinical orthopaedics and related research, 2008Co-Authors: Tsuyoshi Ohishi, M. Takahashi, Akihiro Yamanashi, Daisuke Suzuki, Akira NaganoAbstract:Time-dependent changes in bone markers in delayed or nonunion of vertebral fracture were compared with those of normal union. Thirty-three patients with a fresh vertebral fracture were enrolled. Urinary Type I collagen C-Terminal Telopeptide, pyridinoline, deoxypyridinoline, serum C-Terminal Telopeptide, and N-midportion of osteocalcin (OCN-mid) were determined at the time of hospital admission (within 24 hours after the fracture event in all cases) and at 2, 4, 12, 24, and 48 weeks thereafter. Subjects were divided into two groups according to the results of MR images taken 48 weeks after fracture. Twenty-four were normally united (Group N) and nine had delayed or nonunion (Group D) of the spine. No differences between values of bone resorption markers in Group N and Group D were observed at any time. Serum OCN-mid in Group N started to increase at 2 weeks and reached the peak value at 24 weeks (180%); however, serum OCN-mid in Group D increased at most 120% from baseline to 4 weeks. Values of serum OCN-mid in Group N were higher at 24 and 48 weeks than those in Group D. Impairment of fracture healing was strongly associated with a deficit in the increase of osteocalcin in the later stage of fracture repair.
-
Longitudinal changes of biochemical markers and bone mineral density in hyperthyroid patients during antithyroid drug therapy
Journal of Rural Medicine, 2007Co-Authors: Tsuyoshi Ohishi, M. Takahashi, Michio Oikawa, Akira Nagano, Jitsuhiro IshigakiAbstract:Objective: The aim of the present study was to clarify whether patients with Graves' disease who have lost bone mass can restore bone mass to age-matched control levels by antithyroid drug therapy.Patient/Materials and Methods: One male and 16 female patients (aged 21-71 years, mean±SE 39.9±16.5) with untreated Graves' disease were included in the study. Methimazole or propylthiouracil was given to all of the patients. Biochemical markers (serum N-mid osteocalcin (OCN-mid), alkaline phosphatase (ALP), type I collagen C-Terminal Telopeptide (sCTx), urinary pyridinoline (Pyr), deoxypyridinoline (Dpyr) and type I collagen C-Terminal Telopeptide (uCTx) and bone mineral density at the distal one third of the radius were assessed prior to treatment, and in the first, third, sixth and twelfth months of treatment.Results: All biochemical markers had increased significantly 12 months after treatment compared with the baseline values (OCN-mid, p
-
THE EFFECT OF MENOPAUSE AND OSTEOPOROSIS WITH FRACTURES ON SERUM C-Terminal Telopeptide OF TYPE I COLLAGEN
2002Co-Authors: K. Kawana, M. Takahashi, H. Hoshino, K. Kushida, A. NaganoAbstract:Aim: Urinary C-Terminal Telopeptide of type I collagen (u-CTx) has been reported to be a sensitive biochemical marker of bone turnover. There have been two assays for urinary CTx, which are u-aCTx and u-BCTx. A newly developed immunoassay for serum CTx (s-CTx) is now available for assessment of bone resorption. We have both evaluated the effects of menopause, and osteoporosis on the measurements of serum CTx and compared them to urinary CTx assays. Subjects: 79 premenopausal healthy women, 80 post-menopausal healthy women, 61 osteoporotic patients with vertebral fractures and 34 osteoporotic patients with hip fractures Results: Bone resorption markers were increased after menopause. There was no significant difference among s-CTx, u-aCTx and u-BCTx in the T-scores of post-menopausal group over premenopausal group (T -score; s-CTx:2.3, u-aCTx:1.8, u-BCTx:2.1). Patients with vertebral fractures and patients with hip fracture had elevated levels of bone resorption markers compared to age-matched healthy postmenopousal women. There was no significant difference among s-CTx, u-aCTx and u-BCTx in the T-scores against postmenopausal group in vertebral fracture group (T -score; s-CTx:0.8, u-aCTx:0.9, u-BCTx:0.7) and in hip fracture group women (T-score; s-CTx:1.1, u-aCTx: 1.3 u-BCTx: 1.3). Conclusions: These findings indicate that s-CTx reflects the increase of bone resorption associated with menopause and osteoporosis with vertebral fractures and hip fractures.
-
Comparison of serum and urinary C-Terminal Telopeptide of type I collagen in aging, menopause and osteoporosis.
Clinica chimica acta; international journal of clinical chemistry, 2002Co-Authors: K. Kawana, M. Takahashi, H. Hoshino, K. KushidaAbstract:Urinary C-Terminal Telopeptide of type I collagen (u-CTx) has been reported to be a sensitive biochemical marker of bone turnover. There have been two assays for urinary CTx, which are alpha-CTx and beta-CTx. A newly developed immunoassay for serum CTx (s-CTx) is now available for assessment of bone resorption. We evaluated the effects of aging, menopause, and osteoporosis on the measurements of serum CTx and compared them to urinary CTx assays. In 79 premenopausal healthy women, 80 postmenopausal healthy women, 61 osteoporotic patients with vertebral fractures and 34 osteoporotic patients with hip fractures, s-CTx and urinary beta-CTx (u-betaCTx) were measured by ELISAs, and urinary alpha-CTx (u-alphaCTx) was measured by an RIA. In all subjects, s-CTx significantly correlated with both u-alphaCTx (r=0.54) and u-betaCTx (r=0.51). There was no significant difference among s-CTx, u-alphaCTx and u-betaCTx in the T-scores of the postmenopausal group over the premenopausal group. These findings indicate that the value of s-CTx, as well as urinary CTxs, reflected the increase of bone resorption associated with menopause with a high degree of sensitivity. Patients with vertebral fractures had moderately increased concentrations of bone resorption markers compared to age-matched healthy postmenopausal women (T-score; s-CTx: 0.8, u-alphaCTx: 0.9, u-betaCTx: 0.7), whereas bone resorption markers in hip fracture patients were greatly increased compared to healthy postmenopausal women (T-score; s-CTx: 1.1, u-alphaCTx: 1.3 u-betaCTx: 1.3). The T-scores of u-CTxs against the postmenopausal group in vertebral fracture group and in hip fracture group were not significantly different from those of s-CTx. s-CTx, as well as urinary CTxs, reflects the increase of bone resorption in patients with vertebral fractures and hip fractures.